Member Info for Breq

Guessing a dividend will be announced to compensate for almost 5 month lock in. If so, then £2.50 payable in mid Sep maybe. That would equal 10 weeks of operating cashflow since 30 June cash balance figure in RNS. So no fall in cash balance except for capex during 10 period.

Anticipating relist on Monday. Hoping for prospectus Friday afternoon. Would be a ‘fair’ way to give shareholders time to make a decision on sell, hold, or buy.

Let’s hope it’s Christmas Eve not Dec 17 !

Hoping for another acquisition of maybe 10,000 boed over next few months. Smaller than current RRE so won’t need a share suspension. Then producing 30,000 boed plus. Then Total size - 25,000 boed for $635 m - deal in H1 2020. Once again no share suspension needed I think. Not unrealistic to see 50,000 boed in a year’s time now RRE has now reached a good size.

Hope they do more share buy backs. Think the LSE would give AA an OK on owning over 30% if resulting from a share buy back. I think they do that.
If not, then all AA has to do is sell an equivalent percentage of his shares into the buy back to maintain his current ( under 30%) percentage shareholding. He'd receive cash plus maintain his ownership interest. Maybe even under the low tax 10% Entrepreneurs' Relief scheme. Would like to see Rockrose with 10 million shares outstanding within a year.

Seen some comments about H1 production of 22,000 boed being a touch below some peoples' expectations. From the annual report, there's been a 'walk to work' maintenance session at Bleo Holm over the past month. Maybe that reduced H1 production a bit. Maybe the prospectus will tell us.
Hoping to buy some more shares if there's some profit taking by locked in shareholders at relist.

Obviously don't know if it's Liberum, but see one of their healthcare people has a degree in biochemistry and molecular biology from Oxford and lots of big broker pharma experience.
Anyway we'll find out soon for certain.

Looks like next Wed's Liberum roundtable is institutions only by invite only. So maybe a broker announcement RNS on Tuesday or Wednesday ? If it's them.
Whoever it is, really looking forward to the broker initiation note. Should be a good 20 pages or more of detail. Should highlight this crazy low current valuation.

Think so. Go to Liberum's Linkedin and look at a post 2 days ago.

Broker - Liberum - is hosting a roundtable next week with NFX as one of the few companies on the panel. Maybe - just a guess - Liberum is the new broker. I like them. Better than most.

Maybe the broker beauty parade has provided a more comprehensive understanding of NFX in the city. If you can't get the broker role then at least you can get some of your clients in before the next move up.

Back in the '90s there was a saying at Microsoft that lots of people owned $100,000 snowmobiles. When Microsoft IPO'd in 1986 quite a few employees cashed in shares and bought snowmobiles - in those days you could buy them for $2,000 each. Microsoft's share price went up 50 times over the next 10 years.
Wondering if NFX shareholders are looking at £4m Porsches or similar this weekend.

Oops I mean $30m of debt cleared in 75 days with average $400,000 of free cash flow a day.

Think debt should be zero by end June .
Producing around 14,000 + barrels now at $50 or more margin so $ 700,000 a day cash flow. Cap Ex for 2019 is around $ 100 m so $300,000 a day roughly. That gives $ 400,000 of free cash flow per day plus uplift for rest of year as more barrels come on line.
Debt was $ 30 m at beginning of year so around 130 days of cash flow.
So maybe debt paid off already.
We should know next week.

LifeArc just sold its royalty interest in Keytruda for $ 1.3bn.
Recent LifeArc CEO and Nuformix founder director is David Tapolczay.
Methinks these NFX people like big royalties.
Fingers crossed for NXP001 results.

Wondering if the faster absorbed NXP001 might be orientated towards migraine. Interesting research over last few years suggesting Emend molecule has action against migraine.
Just guessing latest £500,000 payment is based on speed of absorption. Could be amazing if migraine one of the targets. Wiki tells me 38m migraine sufferers in US alone. Speed of action obviously crucial.
All just guesses. Good luck to all.

Maybe the board are approving the accounts during the day.

Maybe it's a bit delayed as the board are saying -

What! We've got that much cash!
I've got to talk to my tax adviser, that's one hell of a dividend!

Here's hoping.

Don't think you've offended anyone - at least not here.

Good things about Tekcapital is they've got several shots at goal. They also search through tens of thousands of patents to find the most promising using industry experts. So a high chance some of their portfolio will come good. All for a crazy low market cap of £ 6.5m. Just one winner makes this a 10+ bagger.

Don't think the management teams at their portfolio companies would have joined if they didn't like the IP and market opportunity. Too much chance of reputation loss if the IP was worthless and the market non-existent.

LEXION,

Good point. Last year was £ 1.50 from memory. Could be up to £ 3 as post Marathon, RRE will have over twice the production and cash flow.
I'm kind of assuming they'll pay it later in the year just to let cash build for a few months but no reason why they shouldn't pay it earlier unless they are closing in on another deal.

Your right, though I would point out that's an accounting thing largely - an increase in net asset value. But the consulting side seems to be growing so hopefully that will generate cash in the future.

I despair of the other board's TEK musings. There's a poster there pontificating about Guident - a cash drain he thinks with no reasoning given. As a general rule of thumb software companies are often high margin and capital light. He can't even spell the company's name.